Home-use treatment for autism using Autowave technology
The Home-Use of Semiconducting QUantum Excitonic Device: Image Converter/Sound Converter/Electromagnetic Converter to Improve Communicative Efforts, Speech, Language and Related Cognitive Functions in Children With Autism
American Federation of Medical Synergetics · NCT03222375
This study is testing a home device that uses special wave technology to see if it can help improve the behavior and thinking skills of people with autism.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 1 Month to 21 Years |
| Sex | All |
| Sponsor | American Federation of Medical Synergetics (other) |
| Locations | 2 sites (Louisville, Kentucky and 1 other locations) |
| Trial ID | NCT03222375 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the use of the SQUED™ Series 28.1, a home-use device designed to treat autism and related conditions through autowave processes. The approach focuses on the interaction of spatial and wave structures within the body, aiming to restore optimal functioning by addressing disruptions caused by natal trauma. Participants will be assessed for their eligibility based on specific criteria related to their clinical diagnosis and history of complications. The study will explore the effectiveness of this innovative treatment in improving cognitive and behavioral outcomes in affected individuals.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with autism or related conditions who have a history of natal trauma and associated cognitive deficits.
Not a fit: Patients without a clinical diagnosis of autism or related conditions, or those without a history of natal trauma, may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this treatment could significantly enhance the quality of life for patients with autism by improving cognitive and communicative functions.
How similar studies have performed: While the approach of using autowave technology is novel, similar studies exploring wave-based therapies have shown promise in other neurological conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of autism or related conditions. * History of Late complications at Natal Trauma: 1. Cerebral level of Natal Trauma - brain injury; 2. Cervical level of Natal Trauma - injury of vertebral; 3. Cerebral anoxia. * Identified language deficit(s) and/or other cognitive or behavioral impairments (which will be specific to each sub-study). * Adequate ability to perform the research tasks set for the Age level: 1. Infant - greater than 1 month to 2 years of age; 2. Child - greater than 2 to 12 years of age; 3. Adolescent - greater than 12 through 21 years of age. * Presence on the Skin of the interruption of Autowave front (interruption of hair separatrix - dorsal/ventral) and/or of the Autowave Reverberators: 1. Photo of Spiral Autowaves, generated by the kernel of Autowave Reverberator - the kernel having an excitation "tongue"; 2. Graphics on tracing paper of Spiral Autowaves, generated by the kernel of Autowave Reverberator - the kernel having an excitation "tongue". * Presence of Clinical protocol CRF-SQUED™: 1. Diagnostics of Autowave reverberators and Nonlinear Control of Autowave reverberators in Active media (Autowave interaction of patient - Algorithmic approach); 2. Mathematical Modeling of Autowave Reverberator and Computational Simulation of the treatment code (Trade Secret), and creation Active medium SQUED™ for a patient; 3. Recording for a patient of treatment code (Trade Secret) - Autowave regime: Hysteresis of Spiral Autowaves; Drift of Spiral Autowaves; Annihilation of Autowave reverberator. * Magnetogram of region of Home-use and Geographic coordinates of Home-use. Exclusion Criteria: * Peripheral blindness - precludes use of Image converter SQUED™ (iSQUED™). * Peripheral deafness - precludes use of Sound converter SQUED™ (sSQUED™). * Any implanted metal device - precludes use of Electromagnetic converter SQUED™ (eSQUED™). * Any implanted cardiac pacemaker - precludes use of Electromagnetic converter SQUED™ (eSQUED™).
Where this trial is running
Louisville, Kentucky and 1 other locations
- World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS — Louisville, Kentucky, United States (RECRUITING)
- Clinic of Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology of the World Organization of Medical Synergetics — Lviv, Solonka Village, Urozayna Street 41, Ukraine (RECRUITING)
Study contacts
- Principal investigator: Yuliya Yaroshuk, M.D.s. Ph.D. — World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS
- Study coordinator: Yuliya Yaroshuk, M.D.s. Ph.D.
- Email: Dr.Yuliya.Yaroshuk@gmail.com
- Phone: 502-338-0861
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Autistic Disorder, Autism Spectrum Disorder, Child Development Disorders, Pervasive, Neurodevelopmental Disorders, Mental Disorders, Asperger's Syndrome, Neurobehavioral Manifestations, Nervous System Diseases